Marta Heloisa LOPES
Biographic Data
| ID | 5620182 |
|---|---|
| NAME | Marta Heloisa LOPES |
| GIVEN NAMES | Marta Heloisa |
| FAMILY NAME | LOPES |
| SIGNATURE | LOPES M H |
| AFFILIATIONS | Faculdade de Medicina da Universidade de São Paulo, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo (SP), Brasil. |
| ORCID | 0000-0001-5236-6248 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Evaluating the safety profile of the CoronaVac in adult and older adult populations
This Phase IV prospective observational study aimed to evaluate the frequency of solicited and unsolicited adverse reactions within seven days following the administration of each dose of CoronaVac (14-day interval) by age group (18–59 years and ≥60 years). Participants (n = 538; 487 adults and 51 older adults) were enrolled from three public health centers in São Paulo, Brazil from May 2021 to January 2022. The study involved a two-dose vaccinat…
Experiência de implantação de um comitê estadual de farmacovigilância na pandemia de covid-19
The pharmacovigilance committee played a significant role in the ESAVI surveillance system during the period of analysis by assisting in the evaluation of more complex cases. It shows potential to contribute positively to strengthening the immunization program, especially within the safe vaccination system framework
No prominent works on this page.
Experiência de implantação de um comitê estadual de farmacovigilância na pandemia de covid-19
The pharmacovigilance committee played a significant role in the ESAVI surveillance system during the period of analysis by assisting in the evaluation of more complex cases. It shows potential to contribute positively to strengthening the immunization program, especially within the safe vaccination system framework
Evaluating the safety profile of the CoronaVac in adult and older adult populations
This Phase IV prospective observational study aimed to evaluate the frequency of solicited and unsolicited adverse reactions within seven days following the administration of each dose of CoronaVac (14-day interval) by age group (18–59 years and ≥60 years). Participants (n = 538; 487 adults and 51 older adults) were enrolled from three public health centers in São Paulo, Brazil from May 2021 to January 2022. The study involved a two-dose vaccinat…
Medicine (2 works) · 2019-20 coronavirus outbreak (1 work) · Adverse effect (1 work) · Coronavirus disease 2019 (COVID-19 (1 work) · COVID-19 and Mental Health (1 work) · Education during COVID-19 pandemic (1 work) · Healthcare Regulation (1 work) · Internal Medicine (1 work) · Observational study (1 work) · Pediatrics (1 work)